Department of Haematology, Hospital Ampang, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor, Malaysia; Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Department of Haematology, Hospital Ampang, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor, Malaysia.
Cancer Genet. 2021 Jan;250-251:20-24. doi: 10.1016/j.cancergen.2020.11.003. Epub 2020 Nov 6.
Acute lymphoblastic leukemia (ALL) cases with e13a3 fusion transcripts are extremely rare. We report a 24-year-old male with Ph-positive (Ph+) ALL with an aberrant e13a3 fusion transcript treated with CD19-specific chimeric antigen receptor T-cell (CAR-T) therapy. He developed refractory disease post-chemotherapy induction, andreceived allogeneic hematopoietic stem cell transplantation (allo-HSCT) after salvage with imatinib in combination with chemotherapy regimen. Unfortunately, the patient relapsed after +90 days post-transplant. He was consented to CAR-T therapy trial and achieved complete remission, highlighting the efficacy of CAR-T treatment in relapsed-refractory B-ALL irrespective of the underlying genetic drivers in leukemia cells .
急性淋巴细胞白血病（ALL）伴有 e13a3 融合转录本的病例极为罕见。我们报告了一例 Ph 阳性（Ph+）ALL 伴异常 e13a3 融合转录本的 24 岁男性患者，采用 CD19 特异性嵌合抗原受体 T 细胞（CAR-T）治疗。他在化疗诱导后出现难治性疾病，并在伊马替尼联合化疗方案挽救治疗后接受异基因造血干细胞移植（allo-HSCT）。不幸的是，移植后 +90 天患者复发。他同意参加 CAR-T 治疗试验并达到完全缓解，这突出了 CAR-T 治疗在复发/难治性 B-ALL 中的疗效，而与白血病细胞中的潜在遗传驱动因素无关。
